RxDoctor Payments Data

Zyad Younan, MD

Clinical Cardiac Electrophysiology · Parlin, NJNPI 1114147220

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,028 of the $24,255 with a category attached, or 66.1%. 18 manufacturers reported payments, led by Medtronic at 43.5% of the total.

$24,255in general payments, 2019–2025

Across 464 payments — averaging $52.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Biosense Webster, Inc.$6K
  • Abbott$3K
  • Boston Scientific$1K
  • Biotronik Inc.$941
  • ZOLL Respicardia, Inc.$629
  • plus $2K from 12 others

What the payments were for

  • Travel & lodging$7,97533%
  • Food & beverage$16,02866%
  • Education$2511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,255 in reported general payments places this provider in the 65th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$433,041
Medicare patients
681
Services billed
4,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban387$457,684
XareltoRivaroxaban99$120,527
EntrestoSacubitril/Valsartan48$73,374
Amiodarone Hcl143$4,555
Nadolol78$3,699
Metoprolol Succinate189$3,526
Flecainide Acetate51$2,137
Nifedipine ErNifedipine44$1,720
Atorvastatin Calcium122$1,322
Eplerenone16$1,028
Lisinopril89$709
ClopidogrelClopidogrel Bisulfate34$686
Losartan Potassium46$655
Amlodipine Besylate66$637
Valsartan24$627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$457,684387 claims
Johnson & JohnsonXarelto$269$120,52799 claims
NovartisEntresto$31$73,37448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Parlin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →